About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

SABR for Renal Tumors | Clinical Trials | Clareo Health

Back to clinical trial search

RECRUITINGNANCT03747133

SABR for Renal Tumors

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. The usual treatment for this type of cancer is surgery. Considering the most common patients are an average age of 65 and some are ...

Lead sponsor: University Health Network, Toronto•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Andrew McPartlin, MD

CONTACT

416-946-4501 andrew.mcpartlin@rmp.uhn.ca

Sponsors

Lead Sponsor

University Health Network, Toronto

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
•Histological or radiological diagnosis of renal tumor
•Inoperable: High risk for surgery or declined surgery
•ECOG performance status of 0-3

Exclusion Criteria

•≥5 active metastases
•Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR
•Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
•Patients with end stage renal failure \> 4(KDOQI guidelines)
•Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis

Related studies

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

NCT00050752 · Renal Tumor Histology, Cutaneous Leiomyoma, and more

Robot-assisted Laparoscopic Partial Nephrectomy Via the Extraperitoneal Approach in the Prone Position Versus the Lateral Position

NCT06572501 · Renal Tumor, Prone Position, and more

Active Not RecruitingPhase 2/3

11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours

NCT06100367 · Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism, and more

Comparing Two Different Approaches in Robotic-Assisted Renal Surgery

NCT05377632 · Renal Tumor

COMPLETEDPhase 2

Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)

NCT02597322 · cT2a N0NxM0 Renal Tumor

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 20, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment45

Start dateNov 2018

Last updatedFeb 20, 2025

Condition

Locations shown

Royal Victoria Regional Health Centre

Barrie, Ontario

University Health Network - Princess Margaret Cancer Centre

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 20, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions